Anaphylaxis Update: Schools and CEC Webinar

To help inform school and CEC staff about adrenaline injector devices in Australia and ASCIA Action Plans, a free webinar was conducted by the National Allergy Strategy in partnership with Allergy & Anaphylaxis Australia and the Australasian Society of Clinical Immunology and Allergy (ASCIA).

The webinar recording is available below along with just over 20 questions that were answered specifically during the webcast.  There are also further written questions and answers available.  

The webinar:

  • Provides information about EpiPen® and Anapen® and what resources are available.
  • Provides information about the new ASCIA Action Plans.
  • Includes responses to participant questions by an expert panel comprising:
    • Dr Katie Frith (Clinical immunology/allergy specialist)
    • Ms Maria Said (National Allergy Strategy Co-chair and Allergy & Anaphylaxis Australia CEO)
    • Ms Briony Tyquin (Clinical nurse consultant – allergy)
    • Ms Val Noble (Clinical nurse consultant – allergy)

Useful links

During the webinar, several resources were referred to. The links to these resources are provided below. 

More Questions and Answers

For more written Q&As from the webcast see:

Webinar with questions

Content updated January 20212

Information Partner


COVID-19 Symptom and Antiviral
Eligibility Checker

COVID-19 Symptom Checker

The National Allergy Council  is a progression of the National Allergy Strategy and remains a partnership between the Australasian Society of Clinical Immunology and Allergy (ASCIA) and Allergy & Anaphylaxis Australia (A&AA), as the leading medical and patient support organisations for allergy in Australia.

This project received funding from the Australian Government Department of Health.

Copyright © 2021 National Allergy Strategy